PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchAn Indian CRO should not assume a foreign clinical-trial sponsor makes its services GST-free. Before setting the price or tax clause, identify the supplier and recipient, map the contracted work to the applicable place-of-supply rules—including the pharmaceutical-sector R&D notification—and test every statutory condition for export of services. If the supply qualifies as an export, it is zero-rated; if it does not, determine the correct classification and GST rate before quoting. The rules below reflect the Indian framework as of 7 October 2026; a particular contract requires a fact-specific review.
What to establish before putting GST in a CRO quote
Start with the supply the CRO is actually agreeing to provide, not a broad label such as “clinical research.” The Central Drugs Standard Control Organization (CDSCO) describes a CRO as a body to which a sponsor may delegate or transfer in writing some or all tasks, duties, or obligations relating to a clinical trial or bioavailability/bioequivalence study. CDSCO also says a valid clinical-trial agreement should be in place before trial-related activity begins. The agreement and statement of work should therefore identify the responsibilities, deliverables, milestones, sites, and parties involved.
Next, confirm which Indian legal entity will invoice and which sponsor entity will receive the service. Establish whether the recipient is a separate legal person or merely another establishment of the same person: the export definition excludes supplies between establishments of a distinct person. Record the recipient’s country and address, contracting and invoicing entities, and payment currency and route.
When a clinical-trial service can be zero-rated as an export
Under section 2(6) of the Integrated Goods and Services Tax Act, export of services requires all of the following conditions to be met:
Recommended Free Tools
#1 Best Overall
- The supplier of the service is located in India.
- The recipient is located outside India.
- The place of supply is outside India.
- Payment is received in convertible foreign exchange, or in Indian rupees where permitted by the Reserve Bank of India.
- The supplier and recipient are not merely establishments of a distinct person under the statutory test.
These conditions are cumulative. A foreign sponsor and an offshore payment do not by themselves establish export treatment; the place of supply and the parties’ legal relationship also matter.
A qualifying export is a zero-rated supply, not an exempt domestic supply. Section 16 provides a route for a registered supplier to make a zero-rated supply without payment of IGST under a bond or letter of undertaking (LUT), and to seek a refund of eligible unutilised input tax credit, subject to the Act and rules. Eligibility and current filing requirements should be confirmed before relying on that treatment.
Why the place of supply needs a service-by-service review
For cross-border services, section 13(2) generally places the supply where the recipient is located, subject to statutory exceptions and notified rules. The location where CRO staff perform work, the country where a sponsor is established, and the location of trial participants or sites are facts to assess—not standalone answers to the place-of-supply question.
Section 13(3) includes rules for certain services supplied in respect of goods made physically available to the supplier and services supplied to an individual who must be physically present with the supplier. Section 13(13) also allows the government to notify place-of-supply rules for effective use and enjoyment. The CRO should map its contracted components to the applicable provisions instead of treating a bundled project as automatically governed by one general rule.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →Pharmaceutical-sector R&D notification
The GST Council’s 37th Meeting material names clinical trials among pharmaceutical-sector R&D services for which a place-of-supply rule based on effective use and enjoyment would be notified. CBIC’s notification index identifies Notification 4/2019-Integrated Tax, dated 30 September 2019, as the section 13(13) notification concerning pharmaceutical-sector R&D services. Its operative wording, conditions, amendments, and application to the CRO’s actual contracted components must be checked before concluding where the place of supply is.
How to treat the 2019 Maharashtra advance ruling
The Maharashtra Authority for Advance Ruling’s decision of 4 May 2019 concerned proposed clinical research services by Cliantha Research Limited for entities outside India. It illustrates the fact-specific place-of-supply issue, but it predates Notification 4/2019-Integrated Tax and is not a universal ruling for all Indian CROs. Read its reasoning and scope alongside the later notification and the current contract facts; do not use it alone to conclude that every such service is taxable or every such service is an export.
How to structure the price and tax clause
Separate the commercial service fee from any expressly identified pass-through or reimbursable items. Do not assume a reimbursement sits outside the taxable value: have the GST treatment of each item reviewed against the contract and applicable rules.
| Quote structure | How to present it | What to settle before signing |
|---|---|---|
| Fee exclusive of applicable GST | State the service fee separately and say that applicable GST will be charged in addition if the supply is determined taxable. | Define who reviews a changed tax determination, what evidence is required, and how any resulting tax adjustment is invoiced or credited. |
| Fee inclusive of applicable GST | State that the agreed total includes any GST found applicable, rather than leaving the tax treatment implicit. | Agree how the parties will handle a later change in tax treatment and whether it changes the CRO’s retained fee or the sponsor’s total payment. |
| Zero-rated treatment under bond/LUT | Identify the supply as zero-rated only after the export conditions and applicable place-of-supply rule have been assessed; do not present it as an exemption. | Assign responsibility for maintaining export evidence and completing current LUT, return, and refund steps, where relevant. |
These are commercial drafting options, not statutory contract forms. The quote should align with the statement of work and the actual service bundle; avoid using one undifferentiated “clinical research” description where separately identifiable components may have different tax treatment.
What GST means for the CRO’s cash flow
Zero-rating does not mean the CRO has no GST-related costs or working-capital exposure. Eligible input tax credit and refund mechanisms are subject to statutory conditions, and a refund may not arrive when the CRO incurs the underlying costs. Model eligible credits and the expected timing of any refund as cash-flow items rather than assuming immediate recovery or building in an unsupported market-wide GST premium.
Keep documentation that supports the recipient’s identity and location, the parties’ establishment status, the services actually supplied, and receipt of consideration through the relevant payment route. The statement of work, invoice, payment evidence, and tax analysis should tell a consistent story.
Do not assume one GST rate for every CRO service
CBIC’s rate table lists 18% for “other services” under heading 9989. That entry alone does not establish that every clinical-trial service or CRO bundle falls under that heading or bears that rate. If the supply is taxable, confirm the applicable service classification, whether components of a bundle need separate treatment, and the current rate notification before inserting a percentage in the quote. A taxable domestic or inter-state service is not the same thing as a qualifying zero-rated export.
A practical review sequence before a quote is final
- Define the scope: align the agreement and statement of work with the actual CRO tasks, deliverables, milestones, trial sites, and any separately identifiable components.
- Identify the entities: establish the Indian invoicing supplier, the sponsor recipient, their locations, and whether they are distinct legal persons or establishments of the same person.
- Determine place of supply: analyze section 13’s general rule and relevant exceptions, then check the pharmaceutical-sector R&D notification and its current application to each contracted component.
- Test export eligibility: verify every section 2(6) condition, including place of supply, qualifying payment, and the distinct-person limitation.
- Set the tax mechanics: if the supply qualifies, confirm current bond/LUT and refund requirements; otherwise, verify classification and rate. Specify whether the fee is exclusive or inclusive of applicable GST and how a reasoned tax change will be handled.
- Plan for evidence and cash flow: preserve contract, recipient, and payment records, and model eligible credit or refund timing rather than assuming instant recovery.
The cited statutory and administrative materials establish the framework, not the result for a particular CRO contract. Obtain contract-specific Indian GST advice before fixing the tax clause or claiming zero-rating.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
